MIV Therapeutics war gestern schon bei + 50 % in den USA - 500 Beiträge pro Seite

[gony2]

MIV Therapeutics war gestern schon bei über 50 % + in den USA und hat bei +30 % geschlossen. Umsatzvolumen gestern fast vervierfacht. Seit einigen Wochen wird MIV auch in Deutschland gehandelt und es geht stetig nach oben.
Das Handelsvolumen für einen Small Cap Wert aus den USA ist in Deutschland erheblich wenn mann bedenkt das z.B. hier im Board nur geringes Intresse besteht. Da werden wohl Positionen für später aufgebaut. Der Kauf läut am besten über Frankfurt. Bin mal gespannt wie es heute weitergeht. Als Tip für die Käufer: Verlagert eure Käufe auf den nachmittag den da fällt der Kurs in FFm immer. Also viel Spaß mit MIV

[gony2]

Hier sind alle Infos in einer Studie über MIV zusammengefasst

http://img.wallstreet-online.de/news_docs/466/200502/_ISM_Re…

[gony2]

Erst mal auf Englisch

MIV Therapeutics Inc.´s HAp Nano Stent Coating Demonstrates Excellent Biocompatibility and Safety in Coronary Arteries
MIV Therapeutics Inc.`s HAp Nano Stent Coating Demonstrates Excellent Biocompatibility and Safety in Coronary Arteries



BW5363 MAR 08,2005 3:03 PACIFIC 06:03 EASTERN



( BW)(MIV-THERAPEUTICS-INC)(MIVT) MIV Therapeutics Inc.´s HAp NanoStent Coating Demonstrates Excellent Biocompatibility and Safety inCoronary Arteries

Business Editors/Health/Medical Writers

VANCOUVER, British Columbia--(BUSINESS WIRE)--March 8, 2005--MIVTherapeutics Inc. (OTCBB:MIVT), a developer of next-generationdrug-eluting coatings that inhibit the rejection of implanted medicaldevices, announced today the successful completion of pilotpreclinical studies of hydroxyapatite (HAp) coated stents in pigcoronary arteries. The histopathology studies that followedangiographic and intravascular ultrasound evaluation confirmedexcellent biocompatibility and safety of its proprietaryhydroxyapatite (HAp) coating for vascular applications.
The 28-day safety study was performed on four differentformulations of MIVT´s biocompatible hydroxyapatite (HAp) nano-filmcoating specifically designed for cardiovascular stents, vascularapplications, and use in a broad range of other implantable medicaldevices. Stents coated with MIVT´s proprietary coating demonstratedsuperb safety and healing properties when implanted in pig coronaryarteries.
"The stents coated with hydroxyapatite have demonstrated excellentbiocompatibility and safety of our proprietary coating technology. Thelow amount of produced neointima ranks with the best contemporary baremetal stents and some drug-eluting stents described in literatureutilizing a similar experimental setting. This remarkable result givesus a solid foundation for pivotal pre-clinical safety studies andsubsequent clinical studies," said Alan Lindsay, Chairman, Presidentand CEO of MIVT.
The animal trial was conducted at the Methodist DeBakey HeartCenter, Houston, Texas, by Greg L. Kaluza, M.D., Ph.D., FACC, whosummarized: "The study was extremely successful in yielding consistentand clearly interpretable data despite its exploratory character. Allfour variants of the hydroxyapatite coated stents have deployed veryeasily, had favorable presentation in angiography and intravascularultrasound, and demonstrated excellent safety and biocompatibility byhistology. It has to be noted that such biocompatibility of coatedstainless steel surface has been rarely found in polymer stentcoatings currently dominating the field. The results obtained in thepresent pilot study with hydroxyapatite, a material naturallyoccurring in the body, offer a promise of a uniquely favorable safetyand biocompatibility profile, rarely matched in the endovascularsetting."
The histology studies were supervised by Fred J. Clubb, Jr., DVM,Ph.D., Director of Research at the Cardiovascular PathologyLaboratory, Texas Heart Institute, Houston, Texas, who concluded inhis report: "Four studied stent groups coated with different coatingtechnologies did not induce excessive vascular changes. Results ofthis study suggest that the stents coated with MIVT Hydroxyapatitecoating could be safe for clinical trials."
Neither of the above institutions, nor the investigators involvedin the above study, had any vested interest in the sponsors of thestudy.
Dr. Dov Shimon, Chief Medical Officer of MIV Therapeutics andHeart Surgeon, added, "In all investigational groups evaluated in thisstudy the endothelialization of all study stents was complete at28-days. Moreover, there was no significant residual fibrin visible onthe luminal surface or around the stent struts. All the histologyparameters were very uniform and on par with the bare metal stents.Bare metal stent surface has been so far unmatched in vascularcompatibility. Competitive coatings specifically designed with anobjective to decrease thrombogenicity, such as heparin orphosphorylcholine, have failed to be clinically superior to stainlesssteel. Thus, this equivalence of HAp coating to stainless steel is anextremely valuable and encouraging finding."

About the Methodist DeBakey Heart Center and Texas HeartInstitute, Houston, Texas

The Methodist DeBakey Heart Center and the Texas Heart Institute,Houston, Texas, are leading clinical, academic and scientific researchinstitutions. Both institutions are globally recognized as leadingcardiovascular centers. Pioneering work and contributions in thefields of heart surgery, congenital heart disease, aortic surgery,heart transplantation, vascular surgery, and invasive cardiology haveplaced these centers as pillars of excellence.

About MIV Therapeutics

MIV Therapeutics is developing a next generation line of advancedbiocompatible coatings for passive and drug-eluting application oncardiovascular stents and other implantable medical devices. MIVT´sultra-thin coating has been derived from a unique biocompatiblematerial called Hydroxyapatite (HAp) that has been shown tosignificantly inhibit the body´s inflammatory response and the problemof restenosis associated with implanted medical devices.Hydroxyapatite is a biocompatible and bioactive porous material thatmakes up the bone mineral and matrix of teeth. It is widely used as abone substitute material and for coating implantable fixation devicesin orthopedic, dental and other applications. A Collaborative ResearchAgreement (CRA) between MIVT and the University of British Columbiareceived a research and development grant from the Natural Sciencesand Engineering Research Council of Canada (NSERC) in 2002 for theadditional development of Hydroxyapatite as a drug eluting coating.MIVT´s ultra-thin coating formulation is designed primarily to protectsurrounding tissue from the chemical interaction of metal stents. TheCompany has progressed to the next development stage, which isexpected to finalize the drug-eluting research and developmentprogram.